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Summary Lung function in cases of chronic airflow obstruction (CAO) due to
tuberculous destroyed lung, which is still common in Korea, has not been objectively
investigated. We evaluated lung functions and postbronchodilator responses in 21
CAO patients with a forced expiratory volume in 1 s (FEV1) of 30–65% of the predicted
value, and compared some of these results with those of age-, sex- and FEV1%
predicted-matched patients with chronic obstructive pulmonary disease (COPD). In
addition, we analyzed the lung functions of CAO patients with respect to wheezing.
The forced vital capacity (FVC) (Po0:05) and postbronchodilator FEV1 of CAO patients
were lower than those of COPD patients (Po0:05). When a positive bronchodilator
response was defined as an absolute change of FEV1 (FEV1 Dabs) of more than 0.2 l
(Po0:05) and a percentage of initial FEV1 (FEV1 D%init) of more than 12%, the positive
rates in CAO patients were lower than in COPD patients (Po0:05). Among the CAO
patients, patients with wheezing showed lower forced expiratory flow 25%–75%
(FEF25–75%) (Po0:05) and higher airway resistance than those without wheezing
(Po0:05). CAO patients with wheezing were more responsive to bronchodilator than
those without wheezing. Although the pathophysiology of CAO differs from that of
COPD, bronchodilator therapy could be useful for treating CAO, especially in cases
presenting with wheezing.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Advanced tuberculosis (TB) can cause extensive
destruction of lung parenchyma,1 which occurs
over years in cases of chronic progressive TB, and
this damage causes chronic airflow obstruction
(CAO). Patients having CAO present with clinical
manifestations similar to those of chronic obstruc-
tive pulmonary disease (COPD), but should be
differentiated from patients with COPD. COPD is
one of the most frequent causes of deaths, for
example, more than 100,000 deaths are attributed
to COPD in the United States in 1998,2 and a
smoking history of at least 20 pack-years is the most
important risk factor for COPD.3
Complicated TB is still one of the important
pulmonary disorders in Korea.4,5 Although exten-
sive parenchymal destruction due to TB and
following airflow limitation is clinically common,
the degree of airflow obstruction and bronchodi-
lator responsiveness have not been evaluated
objectively; moreover, treatment guidelines for
those with secondary airflow obstruction may be
confused with those of COPD.
Thus, we compared pulmonary function and
bronchodilator responsiveness in CAO and COPD
patients, and also examined whether differences
exist in lung functions, including bronchodilator
response, of CAO patients with and without
wheezing.
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Patients
The study subjects were patients who visited
Mokdong Hospital, Ewha Womans University, and
presented with dyspnea, cough, sputum and/or
hemoptysis. Subjects were regularly followed up
for more than 6 months and had a forced expiratory
volume in 1 s (FEV1) of 30–65% of the predicted
value, moderate-to-severe pulmonary insufficiency.
We defined CAO patients as those presenting with
lung function insufficiency due to destroyed tuber-
culous lung with a history of TB, parenchymal
damage to more than 1/2 of one lung, no current
evidence of active TB, less than 20 pack-years
smoking history and no current smoking habit.
COPD patients were defined as those presenting
with lung function insufficiency related to smoking
for more than 20 pack-years and no radiologic
evidence of lung infiltration.6 According to above
criteria, we selected 21 CAO patients, of whom 11
male patients were individually age-, sex- and
FEV1% predicted-matched with 11 COPD patients.
The defined range of the age of matched patients
was 75 years from the corresponding CAO patient
value and the defined range of the FEV1% was75%.
We divided 21 CAO patients into two groups: one
consisting of nine subjects who presented with
frequent wheezing in a stable condition during the
follow-up period and the other consisted of 12
subjects without wheezing during their visits.
Methods
For all 21 CAO patients and 11 COPD patients, we
examined chest symptoms that appeared during
the follow-up of more than 6 months, the presence
of wheezing, the history of TB and smoking and
evaluated the number and extent of lung involve-
ment by chest X-ray in CAO patients. We defined
acute exacerbation as an unscheduled visit that
needed intravenous steroid administration, emer-
gency care or admission because of worsening
dyspnea.7 Body mass index (BMI) was calculated
using the weight and height measured at the time
of pulmonary function testing.
Spirometry tests
Pulmonary function testing was done when patients
were stable, and not when they complained of
worsening symptoms, and bronchodilator response
was measured after withdrawal of a b-2 agonist
inhaler for more than 12 h and of theophylline for
more than 48 h. Lung function was measured by
using the 6200 Autobox DL Pulmonary Function
Laboratory from SensorMedics Co. (USA). The
maximum of three measurements taken with good
patient cooperation was selected. Predicted values
were calculated using the formula suggested by
European Respiratory Society.8 Ten to 20min after
inhaling 0.02mg of the b-2 agonist, fenoterol,
triplicate PFT readings were taken and the highest
of the three readings was recorded. In order to
evaluate the bronchodilator response, changes in
FEV1 were defined as follows:
1. Absolute change (FEV1 Dabs): post-FEV1pre-
FEV1.
2. Percentage of initial FEV1 (FEV1 D%init): ((post-
FEV1pre-FEV1)/pre-FEV1) 100.
Positive bronchodilator response was defined
using the criteria after bronchodilator inhalation,
when FEV1 Dabs was more than 0.2 l and FEV1
D%init was more than 12%.9,10
Statistical analysis
All data are expressed means and standard devia-
tions or frequencies. Statistical analysis was per-
formed using SPSS-PC non-parametrically. The
Wilcoxon signed rank test was used to compare
data in paired samples, the McNemar test to
analyze categorical variables in paired samples,
the Wilcoxon rank sum test to compare data in two
independent groups, and the w2 test to analyze
categorical variables in two independent groups.
Statistical significance was accepted for P values
less than 0.05.
Results
Clinical characteristics in CAO and COPD
patients
Mean age of the 21 CAO patients was 56.6713.7
years and 12 patients were male; mean BMI was
21.5 kg/m2; only three patients were ex-smokers
and their mean pack-years was 2.6.
Of 21 CAO patients, 11 were age-, sex-, and
FEV1% predicted-matched to COPD patients. The
mean ages of COPD and CAO patients were
65.277.5 and 65.878.8 years, respectively, and
their average BMIs were 20.571.7 and
20.073.5 kg/m2, respectively. The number of
patients with a smoking history was significantly
higher among COPD patients than among CAO
patients (Po0:001), and the number of calculated
pack-years was significantly higher in COPD
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patients (Po0:01). In terms of the respiratory
symptoms of CAO patients, the frequency of
hemoptysis was higher, but without statistical
significance, than in COPD patients (Table 1).
Lung function in CAO patients
Mean forced vital capacity (FVC) was 58.0712.5%
of the predicted value, FEV1 42.7710.9% and total
lung capacity (TLC) 112.2748.5%. In terms of the
two criteria of a positive bronchodilator response
after bronchodilator inhalation, when FEV1 Dabs
was more than 0.2 l and FEV1 D%init was more than
12%, the positive responses among CAO patients
were 14% and 48%, respectively.
Comparison of lung function between COPD
and CAO patients
The mean FVC of CAO patients was 2.1470.73 l,
which was significantly lower than the 2.6070.69 l
of COPD patients (Po0:05), and the average FVC%
predicted was also significantly lower in CAO
patients (57.9714.8% vs. 70.0714.8%; Po0:01).
Following the bronchodilator inhalation, FEV1 of
CAO patients was significantly lower than that of
COPD patients (1.1570.30% vs. 1.3770.44l%;
Po0:05). Furthermore, FEV1 Dabs (Po0:05) and
FEV1 D%init in CAO patients were significantly lower
than in COPD patients (Po0:05). When a positive
bronchodilator response was defined as an FEV1
Dabs of more than 0.2 l (0% vs. 55%; Po0:05) and an
FEV1 D%init of more than 12%, the positive rates in
CAO patients were significantly lower than in COPD
patients (27% vs. 82%; Po0:05). Airway resistance
(Raw) in CAO patients was higher than in
COPD patients, but without statistical significance
(Table 2).
Comparison of clinical characteristics in the
presence or absence of wheezing in CAO
patients
When CAO patients were divided into two groups
according to the presence or absence of a wheezing
sound, no differences were found in age, height,
weight, BMI, smoking history, follow-up period,
number of exacerbation episodes during the follow-
up period or hospitalization rate, or for each
respiratory symptom. More cases in both groups
showed upper lobe infiltration than lower lobe
infiltration by chest X-ray. Left lung involvement
was more prevalent in wheezing group without
statistical significance (Table 3).
ARTICLE IN PRESS
Table 1 Clinical characteristics in all CAO patients and age-, sex-, and FEV1% predicted-matched COPD and CAO
patients.
Variables All CAO ðn ¼ 21Þ COPD ðn ¼ 11Þ CAO ðn ¼ 11Þ
Mean SD Mean SD Mean SD
Age (years) 56.6 13.7 65.2 7.5 65.8 8.8
Male sex (%) 57 F 100 F 100 F
Height (m) 1.62 0.09 1.65 0.06 1.64 0.10
Weight (kg) 57.0 12.2 56.3 7.6 54.2 12.3
BMI (kg/m2) 21.5 4.0 20.5 1.7 20.0 3.5
Smoking history (%) 16 F 100 F 18nn
Ex-smoker (%) 16 F 27 F 18
Current smoker (%) 0 F 73 F 0.0
Amount of smoking (pack-years) 2.6 6.5 44.1 23.3 3.6n 8.1
Duration of follow-up (months) 16.0 19.7 15.1 14.6 16.0 19.7
No. of exacerbation episodes 1.0 1.1 0.7 1.2 1.0 1.1
Hospitalization rate (%) 48 F 46 F 55
Symptoms
Dyspnea (%) 86 F 73 F 82 F
Cough (%) 24 F 18 F 9 F
Sputum (%) 24 F 27 F 27 F
Hemoptysis (%) 19 F 0 F 27 F
nPo0:01:nnPo0:001 vs. COPD patients.
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Comparison of lung function in the presence
or absence of wheezing in CAO patients
The forced expiratory flow 25–75% (FEF25–75%) %
predicted was lower in the wheezing group than in
the non-wheezing group (14.876.4% vs.
24.7712.8%; Po0:05), whereas Raw was increased
(859.47426.8% vs. 464.27186.5%; Po0:05). In
terms of bronchodilator response, the positive
rates in the wheezing group were higher than in
non-wheezing group, without statistical signifi-
cance (Table 4).
Discussion
TB can cause progressive, extensive destruction of
areas of one or both lungs. Severe lung damage
typically results from years of chronic TB in
patients who temporarily discontinue chemother-
apy.1,11 Damage to bronchi results from extensive
fibrosis or endobronchial stricture, as tuberculous
sequelae cause airflow obstruction.12 In Korea
where patients with destroyed lung due to TB
account for a significant portion of those with
chronic airflow obstruction, the mechanism of CAO
and clinical issues should be evaluated and differ-
entiated from other sources of chronic airflow
limitation. Increasing extent of disease, increasing
age and location of involved bronchi can all affect
airflow.12,13 In order to evaluate lung function and
postbronchodilator response in patients who suffer
from symptoms due to secondary airflow obstruc-
tion following TB, we selected age-, sex- and FEV1%
predicted-matched COPD patients as a control
group, and performed a case–control study. COPD
is a disease categorized by airflow obstruction,
which is generally irreversible and progressive.6
Our study revealed that the BMIs of all patients
with airflow obstruction were low, which is con-
sistent with previous studies.14 Of the respiratory
symptoms, hemoptysis was found to be more
frequent in CAO patients than in COPD patients,
because secondary bronchiectatic change was more
commonly accompanied by tuberculous destroyed
lung. Greater lung volume loss in CAO patients
seems to be due to parenchymal injury and the
subsequent fibrotic process. In addition, CAO
patients had higher airflow resistance and lower
positive bronchodilator response rates than COPD
patients, probably due to the irreversibility of
anatomical airway constriction in CAO.
Most of the lobes destroyed by TB were upper
lobes by the chest X-rays of CAO patients, and cases
with left lung involvement frequently presented
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Table 2 Lung function and postbronchodilator response in COPD and CAO patients.
Variables COPD ðn ¼ 11Þ CAO ðn ¼ 11Þ
Mean SD % predicted Mean SD % predicted
FVC (l) 2.60 0.69 70.0 2.14n 0.73 57.9nn
FEV1 (l) 1.12 0.29 42.7 1.08 0.30 42.4
FEF25–75% (l/s) 0.48 0.15 18.1 0.55 0.28 21.4
VC (l) 2.66 0.73 69.6 1.78 0.60 53.4
TLC (l) 6.69 0.94 123.7 6.02 1.72 129.1
RV (l) 4.06 0.71 192.9 4.26 1.73 226.9
RV/TLC (%) 60.9 9.2 F 69.6 9.3 F
DLco (ml/min/mmHg) 14.5 4.3 92.9 12.5 8.6 76.5
Raw (cmH2O/l/s) 5.77 2.67 436.2 9.82 5.99 700.8
Post-FEV1 (l) 1.37 0.44 F 1.15
n 0.30 F
FEV1 Dabs (l) 0.26 0.18 F 0.08
n 0.05 F
FEV1 D%init (%) 21.4 12.7 F 7.5
n 5.5 F
Positive bronchodilator response
FEV1 Dabs X0.2 l (%) 55 F F 0
n F F
FEV1 D%init X12% (%) 82 F F 27
n F F
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; FEF2575%: forced expiratory flow 25–75%; VC: vital capacity;
TLC: total lung capacity; RV: residual volume; DLco: carbon monoxide diffusing capacity; Raw: airway resistance; FEV1 Dabs:
absolute change of FEV1; FEV1 D%init: percentage of initial FEV1.
nPo0:05:
nnPo0:01 vs. COPD patients.
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with wheezing. The left lung is prone to luminal
obstruction and atelectasis in severe infection due
to several anatomical features,13,15–17 which causes
it to produce a wheezing sound more so than the
right. Among CAO patients, those with a wheezing
showed lower FEF25–75% and higher Raw than those
without wheezing, suggesting more severe airflow
obstruction in the wheezing group.
Our study has some limitations. The number of
cases involved was small. Coexisting COPD could
not be completely excluded in CAO patients18 and
some patients in both groups may have had
coexistent asthma; however, both groups had low
FEV1 values, such as at 30–65% of the predicted
values, and the two groups were different in as
much as the COPD patients had a history of more
than 20 pack-years of cigarette smoking; and CAO
patients had definite destroyed lung by chest X-ray.
The extent of emphysematous change has been
reported to be correlated with the severity of
airflow obstruction,19 but this study did not
evaluate coexisting emphysema using high-resolu-
tion computed tomogram, although emphysema in
CAO was considered a secondary change due to the
traction induced by extensive scarring.20 In this
study, while some patients showed very low carbon
monoxide (CO) diffusing capacity (DLco); however,
the mean DLco in CAO and COPD patients were not
low. The majority of subjects in this study may have
had chronic bronchitis rather than emphysema,
because the mean DLco was relatively normal in
spite of moderate-to-severe airflow obstruction.
Actually, those patients with 30–40% of the pre-
dicted DLco had a large TLC, suggesting the
hyperinflation found in emphysema.
Although wheezing is arbitrary at times and may
be attributed to several causes, auscultatory
wheezing in CAO patients could be a positive
indicator for bronchodilator therapy regardless of
an association with an asthmatic component. As
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Table 3 Clinical characteristics in CAO patients in terms of wheezing.
Variables No wheezing ðn ¼ 12Þ Wheezing ðn ¼ 9Þ
Mean SD Mean SD
Age (years) 58.4 14.7 54.1 12.8
Male sex (%) 58 F 56 F
Height (m) 1.60 0.09 1.65 0.08
Weight (kg) 53.4 14.0 61.9 7.5
BMI (kg/m2) 20.8 4.7 22.3 2.9
Smoking history (%) 20 F 11 F
Ex-smoker (%) 10 F 11 F
Current smoker (%) 10 F 0 F
Amount of smoking (pack-years) 3.0 6.7 2.2 6.7
Duration of follow-up (months) 12.4 14.2 27.4 21.0
No. of exacerbation episodes 0.7 1.2 1.0 1.0
Hospitalization rate (%) 50 F 44 F
Symptoms
Dyspnea (%) 83 F 89 F
Cough (%) 25 F 22 F
Sputum (%) 25 F 22 F
Hemoptysis (%) 17 F 22 F
Destroyed lung in chest X-ray
Number of destroyed lobes 2.5 1.2 2.6 0.9
Right upper lobe (%) 64 F 56 F
Right middle lobe (%) 36 F 0
Right lower lobe (%) 36 F 11 F
Left upper lobe (%) 82 F 100 F
Left lingular lobe (%) 18 F 44 F
Left lower lobe (%) 18 F 44 F
Right lung only (%) 18 F 0 F
Left lung only (%) 36 F 44 F
Both lungs (%) 46 F 56 F
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bronchodilator treatment is useful for the treat-
ment of COPD, even though the bronchodilator
response is not marked,21,22 it is necessary to treat
CAO with a bronchodilator, especially in cases
presenting with wheezing. Large and longitudinal
studies on patients with tuberculous destroyed lung
will be needed to evaluate pulmonary functional
status and to establish treatment guideline based
on those results.
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Table 4 Lung function and postbronchodilator response in CAO patients in terms of wheezing.
Variables No wheezing (n ¼ 12) Wheezing (n ¼ 9)
Mean SD % predicted Mean SD % predicted
FVC (l) 2.03 0.67 59.9 2.07 0.59 55.4
FEV1 (l) 1.15 0.43 46.3 1.02 0.34 38.0
FEF25–75% (l/s) 0.70 0.52 24.7 0.42 0.16 14.8
n
VC (l) 1.68 0.41 57.8 2.20 0.48 54.6
TLC (l) 4.90 1.83 116.5 6.00 0.67 105.4
RV (l) 3.25 2.02 195.3 3.80 0.56 184.0
RV/TLC (%) 62.4 14.3 F 63.6 6.8 F
DLco (ml/min/mmHg) 11.8 5.3 74.4 18.8n 6.3 92.6
Raw (cmH2O/l/s) 6.92 2.80 464.2 11.31 5.86 859.4
n
Post-FEV1 (l) 1.26 0.43 F 1.15 0.34 F
FEV1 Dabs (l) 0.11 0.06 F 0.13 0.09 F
FEV1 D%init (%) 10.6 6.2 F 14.3 14.1 F
Positive bronchodilator response
FEV1 Dabs Z0.2 l (%) 8 F F 22 F F
FEV1 D%init Z12% (%) 42 F F 56 F F
nPo0:05 vs. CAO patients with no wheezing.
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